Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sandvik acquires JKB Medical Technologies
The acquisition is said to strengthen Sandvik’s position in the strategically important and rapidly expanding medical segment. The acquisition will be consolidated from 14 December 2007. Peter Gossas,
The acquisition is said to strengthen Sandvik’s position in the strategically important and rapidly expanding medical segment. The acquisition will be consolidated from 14 December 2007. Peter Gossas,
This Phase I study was a randomized, double-blind, placebo-controlled trial in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics of inhaled ALN-RSV01 administered via nebulizer. All
This second Phase II study is a randomized, double-blind, placebo-controlled, multi-centre trial to determine the effect of QVA149 on lung function in patients with moderate to severe COPD.
The 2007 approvable letter asked the company to conduct – An objective or subjective clinical trial in the elderly; a safety study assessing the rates of adverse events
The drug candidate, TMC435350, recently advanced into Phase II of the clinical trial program. The first Phase IIa study was initiated in Europe by Tibotec Pharmaceuticals at the
Under the terms of the collaboration between Exelixis and GlaxoSmithKline (GSK) initiated in October 2002 and amended in January 2005, GSK’s selection of XL880 entitles Exelixis to a
Efficacy endpoints in this post-operative abdominal surgery trial were the sum of the pain intensity differences (SPID), versus pre-treatment pain scores, over 0-48 hours and 0-24 hours. Patients
Aridol has already been approved in Europe by the mutual recognition procedure and is now awaiting confirmation of national approval in Portugal. Claimed to be a simple-to-use airways
Study 33CL231 will explore the analgesic efficacy of ADL5859 in treating pain associated with diabetic peripheral neuropathy. The study is a double-blind trial expected to enroll approximately 210
The study involves 210 patients with mild to moderate Alzheimer’s disease (AD). The trial is comparing the safety, tolerability and efficacy of either 200 or 400 micrograms of